Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
Accuray (NASDAQ: ARAY) announced a significant milestone as Shandong Cancer Hospital and Institute completed treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. The hospital, which was the first in China to receive the system, can now treat an average of 95 patient treatment fractions daily.
This achievement is particularly significant given China's projected increase in cancer cases, with expectations of 7.1 million diagnoses by 2045, up from 4.8 million in 2022 - a 47% increase. The Tomo C System, based on the helical TomoTherapy® platform, is designed to provide ultra-precise treatments while enabling higher patient throughput, addressing the growing needs of China's underserved radiation therapy market.
Accuray (NASDAQ: ARAY) ha annunciato un traguardo significativo poiché l'Ospedale e Istituto del Cancro di Shandong ha completato il trattamento di 100 pazienti utilizzando il Tomo® C Radiation Treatment Delivery System, un prodotto realizzato in Cina tramite la joint venture CNNC-Accuray. L'ospedale, che è stato il primo in Cina a ricevere il sistema, può ora trattare in media 95 frazioni di trattamento al giorno.
Questo risultato è particolarmente rilevante dato l'aumento previsto dei casi di cancro in Cina, con 7,1 milioni di diagnosi attese entro il 2045, rispetto ai 4,8 milioni del 2022 - un incremento del 47%. Il sistema Tomo C, basato sulla piattaforma helical TomoTherapy®, è progettato per fornire trattamenti ultra-precisi, consentendo una maggiore capacità di trattamento dei pazienti, affrontando le crescenti esigenze del mercato della terapia radiativa in Cina, ancora sottoservito.
Accuray (NASDAQ: ARAY) anunció un hito significativo ya que el Hospital e Instituto de Cáncer de Shandong completó el tratamiento de 100 pacientes utilizando el Tomo® C Radiation Treatment Delivery System, un producto fabricado en China a través de la empresa conjunta CNNC-Accuray. El hospital, que fue el primero en China en recibir el sistema, puede ahora tratar un promedio de 95 fracciones de tratamiento de pacientes diariamente.
Este logro es particularmente significativo dado el aumento proyectado de casos de cáncer en China, con expectativas de 7,1 millones de diagnósticos para 2045, en comparación con 4,8 millones en 2022, lo que representa un incremento del 47%. El sistema Tomo C, basado en la plataforma helical TomoTherapy®, está diseñado para proporcionar tratamientos ultra-precisos permitiendo un mayor volumen de pacientes, abordando así las crecientes necesidades del mercado de terapia de radiación en China, que está subatendido.
Accuray (NASDAQ: ARAY)는 산동 암 병원과 연구소가 Tomo® C Radiation Treatment Delivery System을 사용하여 100명의 환자 치료를 완료하면서 중대한 이정표를 발표했습니다. 이 제품은 CNNC-Accuray 합작 투자로 중국에서 제작되었습니다. 중국에서 시스템을 받은 첫 번째 병원인 이 병원은 이제 평균적으로 매일 95명의 환자 치료 횟수를 처리할 수 있습니다.
이 성과는 2045년까지 710만 건의 진단이 예상되는 중국의 암 환자가 증가할 것으로 예상되는 점에서 특히 중요합니다. 이는 2022년 480만 건에 비해 47% 증가한 수치입니다. 헬리칼 톰오테라피(TomoTherapy®) 플랫폼 기반의 Tomo C 시스템은 초정밀 치료를 제공하도록 설계되었으며, 증가하는 환자 수요를 충족하기 위해 더 많은 환자를 처리할 수 있도록 합니다. 이는 중국의 치료 수요가 많은 방사선 요법 시장의 필요를 다루고 있습니다.
Accuray (NASDAQ: ARAY) a annoncé une étape significative, car l'Hôpital et Institut du Cancer de Shandong a terminé le traitement de 100 patients en utilisant le Tomo® C Radiation Treatment Delivery System, un produit fabriqué en Chine par le biais de la coentreprise CNNC-Accuray. L'hôpital, qui a été le premier en Chine à recevoir ce système, peut désormais traiter en moyenne 95 fractions de traitement par jour.
Cette réussite est particulièrement significative compte tenu de l'augmentation prévue des cas de cancer en Chine, avec des attentes de 7,1 millions de diagnostics d'ici 2045, contre 4,8 millions en 2022 - une augmentation de 47%. Le système Tomo C, basé sur la plateforme hélicoïdale TomoTherapy®, est conçu pour offrir des traitements ultra-précis tout en permettant une augmentation du nombre de patients traités, répondant ainsi aux besoins croissants du marché sous-servi de la radiothérapie en Chine.
Accuray (NASDAQ: ARAY) gab bekannt, dass das Shandong Krebszentrum und Institut einen bedeutenden Meilenstein erreicht hat, da es die Behandlung von 100 Patienten mit dem Tomo® C Radiation Treatment Delivery System abgeschlossen hat, einem Produkt, das in China durch das Joint Venture CNNC-Accuray hergestellt wurde. Das Krankenhaus, das das erste in China war, das das System erhielt, kann nun durchschnittlich 95 Behandlungseinheiten pro Tag durchführen.
Dieser Erfolg ist besonders bedeutend angesichts der prognostizierten Zunahme von Krebsfällen in China, mit Erwartungen von 7,1 Millionen Diagnosen bis 2045, im Vergleich zu 4,8 Millionen im Jahr 2022 - einem Anstieg von 47%. Das Tomo C System, das auf der helical TomoTherapy® Plattform basiert, ist darauf ausgelegt, ultra-präzise Behandlungen anzubieten und gleichzeitig eine höhere Patientenanzahl zu ermöglichen, um den wachsenden Bedürfnissen des unterversorgten Marktes für Strahlentherapie in China gerecht zu werden.
- First successful implementation of Tomo C System in China with 100 patients treated
- System achieves high efficiency with 95 patient treatment fractions per day
- Strategic expansion into China's growing cancer treatment market (47% growth expected by 2045)
- Successful joint venture product deployment with CNNC
- None.
Insights
The successful deployment of the Tomo C System at Shandong Cancer Hospital marks a pivotal moment in Accuray's China strategy, particularly through its CNNC joint venture. The achievement carries several significant market implications:
Market Opportunity Analysis: China's radiotherapy market presents exceptional growth potential, with projected cancer cases increasing from 4.8 million in 2022 to 7.1 million by 2045 - a
Operational Validation: The system's demonstrated capacity of 95 treatment fractions daily at Shandong Hospital provides compelling evidence of operational efficiency, important for market adoption in high-volume medical centers. This throughput capability directly addresses China's healthcare system's scalability requirements.
Strategic Partnership Impact: The CNNC joint venture represents a sophisticated market entry strategy, leveraging local manufacturing and distribution networks while maintaining technology leadership. This approach navigates China's complex regulatory environment while potentially reducing production costs and improving market access.
Competitive Positioning: The successful implementation at a prestigious institution like Shandong Cancer Hospital, which serves 400,000 patients annually, provides valuable reference credentials for further market penetration. The hospital's international collaborations, including with MD Anderson Cancer Center, enhance the system's credibility in the Chinese healthcare ecosystem.
The number of new cancer cases in
"We are proud to support the Shandong Cancer Hospital and Institute team as they enhance their cancer treatment options with the new Tomo C System. I am pleased that a wide range of cancer types were successfully treated among these 100 patients and that the fast speed of treatment is expected to meaningfully increase capacity - enabling them to treat more patients per day," said Suzanne Winter, president and CEO of Accuray.
Continued Ms. Winter, "The system was developed to enable more clinicians in
Shandong Cancer Hospital and Institute, founded in 1958, is a top center for cancer care, research, and prevention in
"The introduction of the Tomo C Radiation Treatment Delivery System, based on the helical TomoTherapy® platform, is a significant milestone in advancing precision radiotherapy for cancer patients," said Prof. Yu, President of Shandong Cancer Hospital. "The TomoTherapy platform has already demonstrated its transformative impact on cancer treatment. With the Tomo C System we can treat an average of 95 patient treatment fractions per day, enabling our team to provide innovative and effective care for more patients and reaffirming our commitment to the "Healthy China Initiative." This achievement sets a new benchmark for cancer care, propelling our efforts to the next level."
The Tomo C System is designed to provide medical care teams with greater certainty in the outcomes they achieve when treating patients with radiotherapy. Each component of the system – from helical imaging and delivery to advanced treatment planning and centralized data management – is designed to work seamlessly together to facilitate fast, ultra-precise treatments while enabling more patients to receive care each day.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding the company's products, services and innovations, including related to the Tomo C Radiation Treatment Delivery System; expectations regarding the company's joint venture in
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
________________________
1International Agency for Research on Cancer, World Health Organization.
https://gco.iarc.fr/tomorrow/en/dataviz/tables?populations=160
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-100-patient-treatment-regimens-completed-in-china-using-the-tomo-c-radiation-treatment-delivery-system-a-cnnc-accuray-joint-venture-product-302355700.html
SOURCE Accuray Incorporated
FAQ
How many patients has the Tomo C System treated at Shandong Cancer Hospital?
What is the daily treatment capacity of ARAY's Tomo C System?
What is the projected growth of cancer cases in China affecting ARAY's market?
Which hospital first received ARAY's Tomo C System in China?
